bug-bounty373
xss267
exploit99
google96
rce92
open-source91
facebook91
csrf73
ai-agents63
account-takeover60
access-control59
bragging-post59
writeup59
microsoft54
apple46
tool46
smart-contract46
ethereum45
defi45
privacy43
privilege-escalation42
ssrf40
sqli39
authentication-bypass39
llm37
web336
opinion35
automation34
code-generation32
machine-learning32
sql-injection32
infrastructure31
information-disclosure30
idor30
cve29
browser29
subdomain-takeover28
api-security27
smart-contract-vulnerability26
rust26
macos24
clickjacking24
performance-optimization24
authentication24
web-security24
reverse-engineering23
pentest23
vulnerability-disclosure23
solidity23
ai-security22
0
2/10
opinion
A psychiatrist critiques Ambien's clinical approval and research methodology, arguing that FDA-approved trials excluded the very populations most likely to use the drug (those with psychiatric comorbidities), while women were underrepresented despite slower drug metabolism leading to driving impairment and accident risk.
pharmaceutical-safety
clinical-research
drug-approval
fda
zolpidem
study-design-critique
adverse-effects
gender-bias-in-research
psychiatric-comorbidity
tolerance-and-dependence
Ambien
zolpidem
FDA
Searle
Owen Scott Muir
NIDA
NIH